Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Gyre Therapeutics (GYRE) Shares Issued (2016 - 2026)

Gyre Therapeutics has reported Shares Issued over the past 12 years, most recently at $362000.0 for Q4 2025.

Quarterly Shares Issued fell 35.13% to $362000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.6 million through Dec 2025, up 1272.55% year-over-year, with the annual reading at $2.4 million for FY2025, 28.69% up from the prior year.
Shares Issued was $362000.0 for Q4 2025 at Gyre Therapeutics, down from $1.3 million in the prior quarter.
Over five years, Shares Issued peaked at $49.3 million in Q1 2021 and troughed at $275000.0 in Q2 2024.
The 3-year median for Shares Issued is $658000.0 (2024), against an average of $8.5 million.
The largest YoY upside for Shares Issued was 8263.64% in 2025 against a maximum downside of 35.13% in 2025.
A 3-year view of Shares Issued shows it stood at $49.3 million in 2021, then plummeted by 98.87% to $558000.0 in 2024, then tumbled by 35.13% to $362000.0 in 2025.
Per Business Quant, the three most recent readings for GYRE's Shares Issued are $362000.0 (Q4 2025), $1.3 million (Q3 2025), and $23.0 million (Q2 2025).